Si Wang

Si Wang

Auto-generated profile, based on publicly available information

Si Wang

Division of Toxicology, Wageningen University, Tuinlaan 5, 6703 HE Wageningen, The Netherlands

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2013 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
JAJac M. M. J. G. Aarts
Jac M. M. J. G. Aarts
SWSi Wang
Si Wang
RHRené Houtman
René Houtman
RBRinie M. G. J. van Beuningen
Rinie M. G. J. van Beuningen
WWWalter M. A. Westerink
Walter M. A. Westerink
TBToine F. H. Bovee
Toine F. H. Bovee

1 April 2009 in Analytica Chimica Acta
Verified
Journal Article
Closed access
JRJeroen C.W. Rijk
Jeroen C.W. Rijk
TBToine F.H. Bovee
Toine F.H. Bovee
SWSi Wang
Si Wang
CPChristof Van Poucke
Christof Van Poucke
CPCarlos Van Peteghem
Carlos Van Peteghem
MNMichel W.F. Nielen
Michel W.F. Nielen

1 September 2014 in Toxicological Sciences
Verified
Journal Article
Open access
PDF file
SWSi Wang
Si Wang
JRJeroen C.W. Rijk
Jeroen C.W. Rijk
HBHarrie T. Besselink
Harrie T. Besselink
RHRené Houtman
René Houtman
APAd A.C.M. Peijnenburg
Ad A.C.M. Peijnenburg
TBToine F.H. Bovee
Toine F.H. Bovee
In the present study, a previously established integrated testing strategy (ITS) for in vitro estrogenicity testing was extended with additional in vitro assays in order to broaden its sensitivity to different modes of action resulting in apparent estrogenicity, i.e., other than estrogen receptor (ER) binding. To this end, an extra set of 10 estrogenic compounds with modes of action in part different from ER binding, were tested in the previously defined ITS, consisting of a yeast estrogen reporter gene assay, an U2OS ERα CALUX reporter gene assay and a cell-free coregulator binding assay. Two androgen reporter gene assays and the enhanced H295R steroidogenesis assay were added to that previous defined ITS. These assays had added value, as several estrogenic model compounds also elicited clear and potent antiandrogenic properties and in addition also showed effects on steroidogenesis that might potentiate their apparent estrogenic effects in vivo. Adding these assays, examining mechanisms of action for estrogenicity apart from ERα binding, gives a more complete and comprehensive assessment of the ability of test compounds to interfere with endocrine signaling. It was concluded that the extended ITS will go beyond in vivo estrogenicity testing by the uterotrophic assay, thereby contributing to the 3R-principles.

19 September 2011 in Environmental Science & Technology
Verified
Journal Article
Closed access
TBToine F.H. Bovee
Toine F.H. Bovee
PHP. J. M. Hendriksen
P. J. M. Hendriksen
LPL. Portier
L. Portier
SWS. Wang
S. Wang
CEC. T. Elliott
C. T. Elliott
LHL. A. P. Hoogenboom
L. A. P. Hoogenboom

1 January 2013 in ALTEX
Verified
Journal Article
Open access
SWSi Wang
Si Wang
To further develop an integrated in vitro testing strategy for replacement of in vivo tests for (anti-)estrogenicity testing, the ligand-modulated interaction of coregulators with estrogen receptor α was assessed using a PamChip® plate. The relative estrogenic potencies determined, based on ERα binding to coregulator peptides in the presence of ligands on the PamChip® plate, were compared to the relative estrogenic potencies as determined in the in vivo uterotrophic assay. The results show that the estrogenic potencies predicted by the 57 coactivators on the peptide microarray for 18 compounds that display a clear E2 dose-dependent response (goodness of fit of a logistic dose-response model of 0.90 or higher) correlated very well with their in vivo potencies in the uterotrophic assay, i.e., coefficient of determination values for 30 coactivators higher than or equal to 0.85. Moreover, this coregulator binding assay is able to distinguish ER agonists from ER antagonists: profiles of selective estrogen receptor modulators, such as tamoxifen, were distinct from those of pure ER agonists, such as dienestrol. Combination of this coregulator binding assay with other types of in vitro assays, e.g., reporter gene assays and the H295R steroidogenesis assay, will frame an in vitro test panel for screening and prioritization of chemicals, thereby contributing to the reduction and ultimately the replacement of animal testing for (anti-)estrogenic effects.

1 February 2012 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
SWSi Wang
Si Wang
JAJac M.M.J.G. Aarts
Jac M.M.J.G. Aarts
NENynke M. Evers
Nynke M. Evers
APAd A.C.M. Peijnenburg
Ad A.C.M. Peijnenburg
IRIvonne Rietjens
Ivonne Rietjens
TBToine F.H. Bovee
Toine F.H. Bovee